PE20190209A1 - Anticuerpos anti-factor bb del complemento y uso de estos - Google Patents
Anticuerpos anti-factor bb del complemento y uso de estosInfo
- Publication number
- PE20190209A1 PE20190209A1 PE2018001946A PE2018001946A PE20190209A1 PE 20190209 A1 PE20190209 A1 PE 20190209A1 PE 2018001946 A PE2018001946 A PE 2018001946A PE 2018001946 A PE2018001946 A PE 2018001946A PE 20190209 A1 PE20190209 A1 PE 20190209A1
- Authority
- PE
- Peru
- Prior art keywords
- antibodies
- factor
- complement
- seq
- complement anti
- Prior art date
Links
- 230000000295 complement effect Effects 0.000 title abstract 2
- 102000003712 Complement factor B Human genes 0.000 abstract 1
- 108090000056 Complement factor B Proteins 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662317897P | 2016-04-04 | 2016-04-04 | |
| PCT/US2017/025784 WO2017176651A1 (en) | 2016-04-04 | 2017-04-03 | Anti-complement factor bb antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20190209A1 true PE20190209A1 (es) | 2019-02-07 |
Family
ID=60000646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018001946A PE20190209A1 (es) | 2016-04-04 | 2017-04-03 | Anticuerpos anti-factor bb del complemento y uso de estos |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US10934347B2 (OSRAM) |
| EP (1) | EP3452510A4 (OSRAM) |
| JP (3) | JP6967528B2 (OSRAM) |
| KR (2) | KR102673420B1 (OSRAM) |
| CN (2) | CN109563158B (OSRAM) |
| AU (2) | AU2017246794B2 (OSRAM) |
| BR (1) | BR112018070357A2 (OSRAM) |
| CA (1) | CA3019332A1 (OSRAM) |
| CL (1) | CL2018002810A1 (OSRAM) |
| CO (1) | CO2018010827A2 (OSRAM) |
| CR (1) | CR20180529A (OSRAM) |
| DO (1) | DOP2018000219A (OSRAM) |
| EA (1) | EA201892225A1 (OSRAM) |
| EC (1) | ECSP18082302A (OSRAM) |
| IL (3) | IL295288B2 (OSRAM) |
| MA (1) | MA44878A (OSRAM) |
| MX (2) | MX2018012176A (OSRAM) |
| MY (1) | MY194603A (OSRAM) |
| PE (1) | PE20190209A1 (OSRAM) |
| PH (1) | PH12018502137A1 (OSRAM) |
| SG (1) | SG11201808525UA (OSRAM) |
| TN (1) | TN2018000341A1 (OSRAM) |
| WO (1) | WO2017176651A1 (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102066996B1 (ko) | 2010-07-28 | 2020-01-17 | 글리크닉 인코포레이티드 | 순차적으로 다중화된 면역글로불린 fc 조성물을 제조하기 위한 천연 인간 단백질 단편들의 융합 단백질 |
| MX394116B (es) | 2015-07-24 | 2025-03-19 | Gliknik Inc | Proteinas de fusion de fragmentos de proteina humana para crear composiciones de fc de inmunoglobulina multimerizada de forma ordenada con union al complemento aumentada. |
| TN2018000341A1 (en) | 2016-04-04 | 2020-06-15 | Bioverativ Usa Inc | ANTl-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF. |
| IL317014A (en) | 2016-12-09 | 2025-01-01 | Gliknik Inc | Production optimization of GL-2045, a multimerization sterol. |
| CN110022898B (zh) | 2016-12-09 | 2023-07-04 | 格利克尼克股份有限公司 | 用多价Fc化合物治疗炎性疾病的方法 |
| JP2020518240A (ja) * | 2017-01-17 | 2020-06-25 | ザ テキサス エー アンド エム ユニバーシティー システム | 標的細胞のエンドリソソーム区画へのカーゴ分子の送達の向上のためのエンドリソソーム標的化コンジュゲート |
| CN111527105B (zh) * | 2017-10-11 | 2024-10-25 | 美国比奥维拉迪维股份有限公司 | 诱导补体活性的方法 |
| CA3085945A1 (en) | 2017-12-19 | 2019-06-27 | The University Of North Carolina At Chapel Hill | Methods and compositions for delivery of viral vectors across the blood-brain barrier |
| CN114728057A (zh) * | 2019-06-27 | 2022-07-08 | 维西欧制药公司 | 用于调节髓系细胞炎性表型的抗cd53组合物和方法及其用途 |
| BR112022000739A2 (pt) * | 2019-07-17 | 2022-04-12 | Gemini Therapeutics Sub Inc | Anticorpos de potencialização de fator h e usos dos mesmos |
| WO2021167949A1 (en) * | 2020-02-18 | 2021-08-26 | Children's Hospital Medical Center | Compositions and methods for treating liver disease |
| MX2022013135A (es) * | 2020-04-20 | 2022-11-10 | Genzyme Corp | Anticuerpos anti-factor bb del complemento humanizados y usos de los mismos. |
| JP7787164B2 (ja) | 2020-09-23 | 2025-12-16 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 補体媒介性障害の治療のための医薬化合物 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4866132A (en) | 1986-04-17 | 1989-09-12 | The Research Foundation Of State University Of New York | Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| ATE120761T1 (de) | 1987-05-21 | 1995-04-15 | Creative Biomolecules Inc | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
| US5256334A (en) | 1988-09-08 | 1993-10-26 | The Research Foundation Of The State University Of New York | Homogeneous radiopaque polymer-organobismuth composites |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| DK0648271T3 (da) | 1991-08-20 | 2003-07-21 | Us Gov Health & Human Serv | Adenovirusmedieret overførsel af gener til mave-/tarmkanal |
| AU665025B2 (en) | 1991-09-23 | 1995-12-14 | Cambridge Antibody Technology Limited | Production of chimeric antibodies - a combinatorial approach |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| CA2145641C (en) | 1992-12-03 | 2008-05-27 | Richard J. Gregory | Pseudo-adenovirus vectors |
| US5346981A (en) | 1993-01-13 | 1994-09-13 | Miles Inc. | Radiopaque polyurethanes |
| CA2115811A1 (en) | 1993-02-17 | 1994-08-18 | Claus Krebber | A method for in vivo selection of ligand-binding proteins |
| JP3532566B2 (ja) | 1993-06-24 | 2004-05-31 | エル． グラハム，フランク | 遺伝子治療のためのアデノウイルスベクター |
| CN1263864C (zh) | 1993-10-25 | 2006-07-12 | 坎吉公司 | 重组腺病毒载体及其使用方法 |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| EP1285960A3 (en) | 1994-12-09 | 2003-05-07 | Imperial College Innovations Limited | Virulence genes from Salmonella typhimurium |
| WO1996019487A1 (en) | 1994-12-22 | 1996-06-27 | Nissan Chemical Industries, Ltd. | Organobismuth derivatives and process for producing the same |
| US5670477A (en) | 1995-04-20 | 1997-09-23 | Joseph F. Poduslo | Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents |
| AU728657B2 (en) | 1996-03-18 | 2001-01-18 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| ATE208629T1 (de) | 1996-08-27 | 2001-11-15 | Chiron Corp | Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6080849A (en) | 1997-09-10 | 2000-06-27 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
| AR014621A1 (es) | 1997-12-12 | 2001-03-28 | Macromed Inc | Un poli (etilenglicol) con forma de estrella, heterofuncional, biocompatible, metodo para su obtencion y metodo para conjugarlo con una proteina |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| DK1355919T3 (da) | 2000-12-12 | 2011-03-14 | Medimmune Llc | Molekyler med længere halveringstider, sammensætninger og anvendelser deraf |
| GB0105924D0 (en) | 2001-03-09 | 2001-04-25 | Microscience Ltd | Promoter |
| EP2340850A1 (en) | 2004-02-10 | 2011-07-06 | The Regents of the University of Colorado, a Body Corporate | Inhibition of factor B, the alternative complement pathway and methods related thereto |
| NZ582684A (en) | 2004-06-18 | 2011-05-27 | Ambrx Inc | Use of an antibody or binding fragment thereof comprising a non naturally encoded amino acid coupled to a linker |
| US20090016959A1 (en) | 2005-02-18 | 2009-01-15 | Richard Beliveau | Delivery of antibodies to the central nervous system |
| US8741260B2 (en) | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
| KR20170002684A (ko) | 2005-11-04 | 2017-01-06 | 제넨테크, 인크. | 안질환 치료를 위한 보체 경로 억제제의 용도 |
| SI2532681T1 (sl) | 2005-12-20 | 2015-03-31 | Sbi Biotech Co., Ltd. | Protitelo proti-ILT7 |
| CN101970002B (zh) * | 2007-08-27 | 2016-05-18 | 诺福麦德治疗学股份有限公司 | 用因子Bb特异性抗体抑制补体活化的方法 |
| AU2008323939A1 (en) * | 2007-11-08 | 2009-05-14 | Genentech, Inc. | Anti-factor B antibodies and their uses |
| WO2009082624A2 (en) * | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
| RU2011125366A (ru) | 2008-12-05 | 2013-01-10 | Ангиочем Инк. | Конъюгаты терапевтических пептидов и их применение |
| CA2776144C (en) * | 2009-09-29 | 2020-10-27 | Fraunhofer Usa, Inc. | Influenza hemagglutinin antibodies, compositions, and related methods |
| HK1199405A1 (en) | 2011-10-27 | 2015-07-03 | Nkt治疗公司 | Humanized antibodies to inkt |
| NZ628804A (en) | 2012-02-24 | 2017-08-25 | Abbvie Stemcentrx Llc | Dll3 modulators and methods of use |
| JP6244350B2 (ja) * | 2012-04-03 | 2017-12-06 | ノーベルメッド セラピューティクス インコーポレイテッド． | ヒト化およびキメラ抗因子Ｂｂ抗体、ならびにその使用 |
| WO2014044793A2 (en) * | 2012-09-20 | 2014-03-27 | Max-Delbrück-Centrum für Molekulare Medizin | Cd22-binding peptides |
| US8945562B2 (en) * | 2012-11-02 | 2015-02-03 | True North Therapeutics, Inc. | Anti-complement C1s antibodies |
| ME03394B (me) | 2013-02-22 | 2020-01-20 | Medimmune Ltd | Antidllз-antitelo-pbd konjugati i nihovа upotreba |
| US9260527B2 (en) * | 2013-03-15 | 2016-02-16 | Sdix, Llc | Anti-human CXCR4 antibodies and methods of making same |
| WO2015051159A1 (en) | 2013-10-02 | 2015-04-09 | The Rockefeller University | Amyloid protofibril antibodies and methods of use thereof |
| AU2015223056B2 (en) | 2014-02-27 | 2020-10-01 | Allergan, Inc. | Complement Factor Bb antibodies |
| JP7014706B2 (ja) | 2015-07-13 | 2022-02-01 | サイトメックス セラピューティクス インコーポレイテッド | 抗ｐｄ－１抗体、活性化可能抗ｐｄ－１抗体、およびその使用方法 |
| TN2018000341A1 (en) | 2016-04-04 | 2020-06-15 | Bioverativ Usa Inc | ANTl-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF. |
| CN111527105B (zh) | 2017-10-11 | 2024-10-25 | 美国比奥维拉迪维股份有限公司 | 诱导补体活性的方法 |
| MX2022013135A (es) | 2020-04-20 | 2022-11-10 | Genzyme Corp | Anticuerpos anti-factor bb del complemento humanizados y usos de los mismos. |
-
2017
- 2017-04-03 TN TNP/2018/000341A patent/TN2018000341A1/en unknown
- 2017-04-03 CN CN201780029742.9A patent/CN109563158B/zh active Active
- 2017-04-03 IL IL295288A patent/IL295288B2/en unknown
- 2017-04-03 MA MA044878A patent/MA44878A/fr unknown
- 2017-04-03 CA CA3019332A patent/CA3019332A1/en active Pending
- 2017-04-03 CR CR20180529A patent/CR20180529A/es unknown
- 2017-04-03 IL IL262010A patent/IL262010B/en unknown
- 2017-04-03 KR KR1020187031483A patent/KR102673420B1/ko active Active
- 2017-04-03 MX MX2018012176A patent/MX2018012176A/es unknown
- 2017-04-03 IL IL311675A patent/IL311675A/en unknown
- 2017-04-03 US US16/091,447 patent/US10934347B2/en active Active
- 2017-04-03 KR KR1020247018546A patent/KR20240096672A/ko active Pending
- 2017-04-03 EP EP17779607.5A patent/EP3452510A4/en active Pending
- 2017-04-03 BR BR112018070357-5A patent/BR112018070357A2/pt active Search and Examination
- 2017-04-03 EA EA201892225A patent/EA201892225A1/ru unknown
- 2017-04-03 PE PE2018001946A patent/PE20190209A1/es unknown
- 2017-04-03 CN CN202210862505.3A patent/CN116790614A/zh active Pending
- 2017-04-03 SG SG11201808525UA patent/SG11201808525UA/en unknown
- 2017-04-03 MY MYPI2018001682A patent/MY194603A/en unknown
- 2017-04-03 WO PCT/US2017/025784 patent/WO2017176651A1/en not_active Ceased
- 2017-04-03 JP JP2018552076A patent/JP6967528B2/ja active Active
- 2017-04-03 AU AU2017246794A patent/AU2017246794B2/en active Active
-
2018
- 2018-10-03 CL CL2018002810A patent/CL2018002810A1/es unknown
- 2018-10-04 PH PH12018502137A patent/PH12018502137A1/en unknown
- 2018-10-04 MX MX2023007149A patent/MX2023007149A/es unknown
- 2018-10-04 DO DO2018000219A patent/DOP2018000219A/es unknown
- 2018-10-09 CO CONC2018/0010827A patent/CO2018010827A2/es unknown
- 2018-10-31 EC ECSENADI201882302A patent/ECSP18082302A/es unknown
-
2021
- 2021-01-19 US US17/151,860 patent/US11851482B2/en active Active
- 2021-09-10 JP JP2021147485A patent/JP7326393B2/ja active Active
-
2023
- 2023-08-02 JP JP2023126155A patent/JP2023139289A/ja active Pending
- 2023-11-08 US US18/504,416 patent/US20240228599A1/en active Pending
-
2024
- 2024-09-30 AU AU2024224000A patent/AU2024224000A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20190209A1 (es) | Anticuerpos anti-factor bb del complemento y uso de estos | |
| ECSP19086810A (es) | Anticuerpos que se unen específicamente a pd-1 y métodos de uso | |
| CY1123972T1 (el) | Θεραπεια συνδυασμου για καρκινο | |
| AR131056A2 (es) | Composiciones para tratar un trastorno hipofosfatémico | |
| CO2020016619A2 (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso | |
| CY1124004T1 (el) | Υποδορια σκευασματα αντισωματων αντι-cd38 και οι χρησεις τους | |
| CL2018001512A1 (es) | Anticuerpos anti-cd73 humanizados. | |
| ECSP17063327A (es) | Receptores de antígeno quiméricos antidll3 y métodos de uso | |
| CO2017005650A2 (es) | Anticuerpos anti-interleucina-33 | |
| CY1122398T1 (el) | Συνδυαστικες θεραπειες με αντισωματα anti-cd38 | |
| CY1122721T1 (el) | Αντισωματα που δεσμευουν αχl | |
| CY1123065T1 (el) | Ανασυνδυασμενα προβιοτικα βακτηριδια | |
| CO2018010458A2 (es) | Composiciones y anticuerpos anti-tim-3 | |
| CY1123290T1 (el) | Ενωσεις και μεθοδοι χρησης | |
| PE20160690A1 (es) | Anticuerpos anti-cd134 (ox40) humanizados y usos de los mismos | |
| EA202092435A2 (ru) | Моноклональные антитела против bcma | |
| MX377716B (es) | Moduladores de aplnr y usos de estos. | |
| EA201791139A1 (ru) | Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены | |
| MX2019010574A (es) | Anticuerpos anti-c5 y su uso. | |
| UY36942A (es) | Proteínas de unión a antígeno que activan el receptor de leptina | |
| EA201792467A1 (ru) | Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены | |
| AR098465A1 (es) | ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN | |
| MX2017005553A (es) | Terapia de combinacion para cancer. | |
| PE20161390A1 (es) | Anticuerpos multiespecificos | |
| PE20150002A1 (es) | Anticuerpos anti-fcrn |